115 related articles for article (PubMed ID: 38460082)
1. Effect of Renal Impairment on Pharmacokinetics and Safety of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor.
Katsube T; Kezbor S; Shimizu R; Kubota R
Infect Dis Ther; 2024 Mar; 13(3):597-607. PubMed ID: 38460082
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
[TBL] [Abstract][Full Text] [Related]
3. A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
Clin Drug Investig; 2023 Oct; 43(10):785-797. PubMed ID: 37798608
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuzaki T; Matsuo Y; Kubota R
Clin Drug Investig; 2023 May; 43(5):335-346. PubMed ID: 37171749
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Fukuhara T; Ichihashi G; Sanaki T; Baba K; Takeda Y; Tsuge Y; Uehara T
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069722. PubMed ID: 36098519
[TBL] [Abstract][Full Text] [Related]
6. A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
Medicine (Baltimore); 2023 Feb; 102(8):e33024. PubMed ID: 36827007
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.
Fukao K; Nobori H; Kuroda T; Baba K; Matsumoto K; Tanaka Y; Tachibana Y; Kato T; Shishido T
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896829
[TBL] [Abstract][Full Text] [Related]
9. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
[TBL] [Abstract][Full Text] [Related]
10. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.
Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Sakaguchi H; Sonoyama T; Ichihashi G; Sanaki T; Baba K; Tsuge Y; Uehara T
Clin Infect Dis; 2023 Apr; 76(8):1403-1411. PubMed ID: 36477182
[TBL] [Abstract][Full Text] [Related]
12. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment.
Boinpally R; Alcorn H; Adams MH; Longstreth J; Edwards J
Clin Drug Investig; 2013 Mar; 33(3):199-206. PubMed ID: 23417352
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
15. Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Dayal S; Aluri J; Hall N; Filippov G; Moline M; Reyderman L; Landry I
Pharmacol Res Perspect; 2021 Apr; 9(2):e00758. PubMed ID: 33822479
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
Chattopadhyay N; Riecke K; Ligges S; Zimmermann T; Halabi A; Schultze-Mosgau MH
Br J Clin Pharmacol; 2019 Sep; 85(9):2011-2021. PubMed ID: 31112623
[TBL] [Abstract][Full Text] [Related]
17. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment.
Tayo B; Taylor L; Sahebkar F; Morrison G
Clin Pharmacokinet; 2020 Jun; 59(6):747-755. PubMed ID: 31802404
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
Nobori H; Baba K; Kuroda T; Baba K; Matsumoto K; Yoshida S; Watari R; Tachibana Y; Kato T; Fukao K
Antiviral Res; 2024 Apr; 224():105852. PubMed ID: 38428748
[TBL] [Abstract][Full Text] [Related]
19. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
Cass LM; Efthymiopoulos C; Marsh J; Bye A
Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
[TBL] [Abstract][Full Text] [Related]
20. Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.
Landry I; Aluri J; Hall N; Filippov G; Dayal S; Moline M; Reyderman L
Pharmacol Res Perspect; 2021 Apr; 9(2):e00734. PubMed ID: 33689224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
